The RNA-dependent RNA polymerase makes a good drug target because it is so essential to the replication strategy of SARS-CoV-2. The researchers behind the Cell study predicted that certain protease-inhibiting HCV drugs might inhibit also the main protease of SARS-CoV-2, known as nsp5. When they used a supercomputer to model and test their theory, all seven HCV drugs did indeed dock at nsp5. Before rush orders of the HCV drug and polymerase inhibitor combo can be placed, the therapy must be tested in animal models and clinical studies. The India-based multinational Cipla already manufactures HCV drugs en masse at low prices.

Source: Forbes May 05, 2021 18:00 UTC